CR20130556A - FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7 - Google Patents

FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7

Info

Publication number
CR20130556A
CR20130556A CR20130556A CR20130556A CR20130556A CR 20130556 A CR20130556 A CR 20130556A CR 20130556 A CR20130556 A CR 20130556A CR 20130556 A CR20130556 A CR 20130556A CR 20130556 A CR20130556 A CR 20130556A
Authority
CR
Costa Rica
Prior art keywords
formulation
antibody anti
antibody
chelator
antioxidant
Prior art date
Application number
CR20130556A
Other languages
English (en)
Inventor
Willow Diluzio
Csanad M Varga
Vaithianathan Palaniappan
Jason Brown
Irving H Fox
Catherine Scholz
Helen Jenkins
Maria Rosario
Phuong Nguyen
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147702&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130556(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of CR20130556A publication Critical patent/CR20130556A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

Se describen formulaciones de anticuerpo que comprende una mezcla de un anticuerpo anti-a4ß7, un antioxidante o quelante y al menos un aminoácido libre.
CR20130556A 2011-05-02 2013-10-29 FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7 CR20130556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481522P 2011-05-02 2011-05-02
US201161544054P 2011-10-06 2011-10-06

Publications (1)

Publication Number Publication Date
CR20130556A true CR20130556A (es) 2014-03-05

Family

ID=46147702

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130556A CR20130556A (es) 2011-05-02 2013-10-29 FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7

Country Status (37)

Country Link
US (6) US10040855B2 (es)
EP (2) EP2704742B1 (es)
JP (5) JP6190359B2 (es)
KR (7) KR102014512B1 (es)
CN (4) CN107998388B (es)
AR (1) AR086238A1 (es)
AU (5) AU2012250872B2 (es)
CA (2) CA3051418C (es)
CL (3) CL2013003145A1 (es)
CO (1) CO6801648A2 (es)
CR (1) CR20130556A (es)
CY (1) CY1119436T1 (es)
DK (1) DK2704742T3 (es)
DO (1) DOP2013000252A (es)
EA (1) EA032625B1 (es)
EC (1) ECSP22046340A (es)
ES (1) ES2646717T3 (es)
GE (1) GEP20186866B (es)
HK (1) HK1253911A1 (es)
HR (1) HRP20171457T1 (es)
HU (1) HUE036664T2 (es)
IL (6) IL305583A (es)
LT (1) LT2704742T (es)
ME (1) ME02858B (es)
MX (4) MX354101B (es)
MY (1) MY188820A (es)
PE (1) PE20141672A1 (es)
PH (2) PH12018502221A1 (es)
PL (1) PL2704742T3 (es)
PT (1) PT2704742T (es)
RS (1) RS56429B1 (es)
SG (1) SG194730A1 (es)
SI (1) SI2704742T1 (es)
TW (5) TWI723339B (es)
UY (1) UY34054A (es)
WO (1) WO2012151247A2 (es)
ZA (2) ZA201308168B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57870B1 (sr) 2010-01-06 2018-12-31 Dyax Corp Proteini koji vezuju kalikrein plazme
KR101867279B1 (ko) * 2010-10-06 2018-06-15 리제너론 파아마슈티컬스, 인크. 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
CN107998388B (zh) * 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂
MX343324B (es) 2011-07-06 2016-11-01 Nestec Sa Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9764093B2 (en) * 2012-11-30 2017-09-19 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
WO2014152232A2 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
CA2917268C (en) * 2013-07-05 2023-11-07 Integra Medical Inc. Oral compositions
CA2930227C (en) * 2013-11-29 2021-09-28 Ares Trading S.A. A liquid formulation of a fusion protein comprising tnfr and fc region
KR102642382B1 (ko) 2014-10-06 2024-02-29 케모센트릭스, 인크. C-c 케모카인 수용체 타입 9 (ccr9)의 억제제 및 항-알파4베타7 인테그린 차단 항체의 조합 요법
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
PL3226895T3 (pl) * 2014-12-03 2020-12-28 Csl Behring Ag Produkt farmaceutyczny o zwiększonej stabilności zawierający immunoglobuliny
BR112017011545A2 (pt) 2014-12-05 2018-03-13 Nestec Sa ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente
EP3237004B1 (en) 2014-12-24 2024-05-08 Takeda Pharmaceutical Company Limited Predicting outcome of treatment with an anti-alpha4 beta7 integrin antibody
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
AU2016243160B2 (en) * 2015-03-30 2022-02-24 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
US10525137B2 (en) * 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
CN116327920A (zh) * 2016-03-14 2023-06-27 千禧制药公司 预防移植物抗宿主疾病的方法
WO2017160700A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
WO2017192867A1 (en) 2016-05-04 2017-11-09 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating inflammatory bowel disease
JP7202893B2 (ja) * 2016-06-12 2023-01-12 武田薬品工業株式会社 炎症性腸疾患を治療する方法
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
MX2019007564A (es) * 2016-12-23 2019-09-06 Serum Institute Of India Pvt Ltd Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion corriente abajo y formulaciones de anticuerpos estables obtenidas a partir de los mismos.
CN108686204A (zh) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 包含组氨酸缓冲体系的英夫利西单抗组合物
WO2018200818A2 (en) * 2017-04-28 2018-11-01 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
CA3072913A1 (en) * 2017-08-25 2019-02-28 Omeros Corporation Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome
AU2019251452A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy's Laboratories Limited Stable antibody formulation
WO2019198100A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Antibody formulation
US20210401982A1 (en) * 2018-04-10 2021-12-30 Dr. Reddy's Laboratories Limited Stable formulations of therapeutic antibody
US20210187107A1 (en) * 2018-08-29 2021-06-24 Glaxosmithkline Intellectual Property Development Limited Methods of preparing stable liquid therapeutic protein compositions
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
AR119268A1 (es) * 2019-06-10 2021-12-09 Millennium Pharm Inc Métodos de purificación de anticuerpos y composiciones de estos
AU2020364436A1 (en) * 2019-10-11 2022-04-21 Dr. Reddy's Laboratories Limited Stable formulation of integrin antibody
TW202222832A (zh) * 2020-07-31 2022-06-16 美商建南德克公司 抗整聯蛋白β７抗體調配物及裝置
EP4259192A1 (en) * 2020-12-09 2023-10-18 Dr. Reddy's Laboratories Limited Stable aqueous buffer free formulation of an integrin antibody
WO2022253994A1 (en) * 2021-06-04 2022-12-08 Polpharma Biologics S.A. Vedolizumab formulation
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
WO2023126411A1 (en) 2021-12-27 2023-07-06 Polpharma Biologics S.A. Vedolizumab formulation
WO2023230620A1 (en) * 2022-05-27 2023-11-30 Sonnet BioTherapeutics, Inc. Il-12-albumin-binding domain fusion protein formulations and methods of use thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
EP0303463B1 (en) 1987-08-11 1994-11-30 The Board Of Trustees Of The Leland Stanford Junior University Method to control leukocyte extravasation
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
WO1990007321A2 (en) 1988-12-23 1990-07-12 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte receptor homing sequences and their uses
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Repression by peptides of lymphocyte binding to vascular endothelium by interaction of extracellular uterine capacitor with connective tissue, and pharmaceutical preparations containing
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CZ282603B6 (cs) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
EP0625912B1 (en) 1992-02-12 1997-04-16 Biogen, Inc. Treatment for inflammatory bowel disease
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1993023526A1 (en) 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
ES2114183T5 (es) 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ES2270425T3 (es) 1994-01-25 2007-04-01 Elan Pharmaceuticals, Inc. Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4.
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
DK0808367T3 (da) 1995-02-10 2007-11-05 Millennium Pharm Inc Vaskulære slimhindeaddressiner samt anvendelse deraf
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
BR0307975A (pt) 2002-02-25 2005-01-11 Elan Pharm Inc Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
CA2485681C (en) 2002-05-24 2012-10-16 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP2256116A3 (en) 2002-11-18 2011-11-16 ChemoCentryx, Inc. Aryl sulfonamides
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
WO2004075913A1 (ja) 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha タンパク質含有安定化製剤
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
SI3530673T1 (sl) 2004-09-03 2022-08-31 Genentech, Inc. Humanizirani antagonisti proti beta7 in njihove uporabe
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2006096490A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders
EP1948691A1 (en) * 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
CA2638811A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
EA018301B1 (ru) 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
EP2109480B1 (en) 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
CA2671968A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US9111016B2 (en) 2007-07-06 2015-08-18 Stereotaxis, Inc. Management of live remote medical display
EA201000785A1 (ru) * 2007-12-13 2011-02-28 Глаксо Груп Лимитед Композиции для доставки в легкие
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
EP2408816B1 (en) 2009-03-20 2019-09-04 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
CN101533504A (zh) * 2009-04-27 2009-09-16 刘文祥 电子医务***及其装置
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
CN107998388B (zh) * 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА

Also Published As

Publication number Publication date
NZ617340A (en) 2015-12-24
TW202317193A (zh) 2023-05-01
PH12019501662A1 (en) 2021-03-15
RS56429B1 (sr) 2018-01-31
CA2834900A1 (en) 2012-11-08
AU2023274233A1 (en) 2023-12-21
KR20180080354A (ko) 2018-07-11
IL272237B (en) 2022-05-01
SI2704742T1 (sl) 2017-12-29
UY34054A (es) 2012-11-30
CA3051418A1 (en) 2012-11-08
TW201300128A (zh) 2013-01-01
CN103533959A (zh) 2014-01-22
PE20141672A1 (es) 2014-11-26
MX367097B (es) 2019-08-05
TW201813665A (zh) 2018-04-16
KR20170056713A (ko) 2017-05-23
KR20230021758A (ko) 2023-02-14
US20210340261A1 (en) 2021-11-04
MX2019009244A (es) 2019-09-13
BR112013028169A2 (pt) 2017-06-27
AU2012250872B2 (en) 2017-07-13
IL274846A (en) 2020-07-30
CN108969469A (zh) 2018-12-11
IL272237A (en) 2020-02-27
KR20200088517A (ko) 2020-07-22
CN108969761A (zh) 2018-12-11
HK1253911A1 (zh) 2019-07-05
ES2646717T3 (es) 2017-12-15
MY188820A (en) 2022-01-05
TWI832619B (zh) 2024-02-11
AR086238A1 (es) 2013-11-27
TW202133878A (zh) 2021-09-16
TWI638661B (zh) 2018-10-21
ZA201707310B (en) 2022-04-28
US20180346578A1 (en) 2018-12-06
TW201940195A (zh) 2019-10-16
CY1119436T1 (el) 2018-03-07
PL2704742T3 (pl) 2018-01-31
KR102136208B1 (ko) 2020-07-21
DOP2013000252A (es) 2013-12-31
JP7107997B2 (ja) 2022-07-27
AU2019216679B2 (en) 2021-09-23
ZA201308168B (en) 2018-11-28
CL2020001579A1 (es) 2020-11-06
JP2020180163A (ja) 2020-11-05
EA201391613A1 (ru) 2014-07-30
CL2017000829A1 (es) 2017-12-29
MX2021008112A (es) 2022-06-02
KR20210120144A (ko) 2021-10-06
US11560434B2 (en) 2023-01-24
IL290848A (en) 2022-04-01
US20180327497A1 (en) 2018-11-15
IL290849A (en) 2022-04-01
KR20190100451A (ko) 2019-08-28
EP2704742B1 (en) 2017-07-12
CN107998388A (zh) 2018-05-08
CN103533959B (zh) 2018-06-05
AU2017204192A1 (en) 2017-07-13
CN107998388B (zh) 2023-07-14
US20230312727A1 (en) 2023-10-05
CA2834900C (en) 2021-03-02
KR102493433B9 (ko) 2023-09-01
WO2012151247A3 (en) 2013-02-28
JP6190359B2 (ja) 2017-08-30
ECSP22046340A (es) 2022-07-29
JP2017137353A (ja) 2017-08-10
JP2022132430A (ja) 2022-09-08
DK2704742T3 (en) 2017-10-23
HUE036664T2 (hu) 2018-07-30
GEP20186866B (en) 2018-06-25
TWI698254B (zh) 2020-07-11
PT2704742T (pt) 2017-11-15
ME02858B (me) 2018-04-20
AU2021225160A1 (en) 2021-09-30
IL229169B (en) 2020-06-30
US20200377601A1 (en) 2020-12-03
CO6801648A2 (es) 2013-11-29
KR102493433B1 (ko) 2023-01-27
EP3311834A1 (en) 2018-04-25
KR102308938B1 (ko) 2021-10-01
SG194730A1 (en) 2013-12-30
WO2012151247A2 (en) 2012-11-08
IL229169A0 (en) 2013-12-31
AU2012250872A1 (en) 2013-11-21
US20140341885A1 (en) 2014-11-20
CL2013003145A1 (es) 2014-07-25
KR102014512B1 (ko) 2019-08-26
AU2019216679A1 (en) 2019-09-05
KR101875155B1 (ko) 2018-07-09
LT2704742T (lt) 2017-10-25
EP2704742A2 (en) 2014-03-12
TWI723339B (zh) 2021-04-01
EA201391613A8 (ru) 2016-05-31
JP2019052191A (ja) 2019-04-04
AU2021225160B2 (en) 2023-12-21
PH12018502221A1 (en) 2019-10-28
MX354101B (es) 2018-02-13
KR20140145952A (ko) 2014-12-24
AU2017204192B2 (en) 2019-09-12
TWI799757B (zh) 2023-04-21
JP6751450B2 (ja) 2020-09-02
IL305583A (en) 2023-10-01
JP6467457B2 (ja) 2019-02-13
JP2014515763A (ja) 2014-07-03
CA3051418C (en) 2021-05-18
EA032625B1 (ru) 2019-06-28
MX2013012725A (es) 2013-12-06
HRP20171457T1 (hr) 2017-11-03
KR101884406B1 (ko) 2018-08-02
US10040855B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
CR20130556A (es) FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
CY1121560T1 (el) Ανοσογονικη συνθεση
AR094204A1 (es) Composiciones para el cuidado oral que contienen haluros de acido amino
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
ECSP13013050A (es) Formulación para anticuerpo anti- 4 7
UY34228A (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9
GT201300213A (es) Derivados de fluoro-piridinona útiles como agentes antibacterianos
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
TR201908003T4 (tr) TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
NI201400042A (es) 2 - tiopirimidinonas
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
BR112014014459A2 (pt) composições para cuidados orais
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
UA113540C2 (xx) Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду
BR112014029264A2 (pt) microcápsulas contendo um oxidável ativa, e um processo para a preparação do mesmo